Neurology:急性缺血性卒中患者再通治疗无效的多变量预测模型

2022-08-31 Naomi MedSci原创

近日,一项发表在Neurology上的研究试图开发和验证一个多变量预后模型,以确定接受这些治疗的患者中无效的再通治疗。该FRT预测模型有助于为共享决策提供信息,并确定在紧急情况下最相关的特征。

背景和目的:1/4的缺血性卒中患者接受静脉溶栓(IVT)和机械取栓(MT)治疗后预后极差,且存在较高的后勤和经济负担。近日,一项发表在Neurology上的研究试图开发和验证一个多变量预后模型,以确定接受这些治疗的患者中无效的再通治疗(FRT)。

材料和方法:纳入接受MT和/或IVT治疗的单一学术卒中中心前瞻性观察登记的患者。数据集被分为训练(N=1808,80%)和内部验证(N=453,20%)队列。使用k-NN补充入院时可用的32个变量后的梯度增强决策树机器学习模型来预测3个月后的FRT,定义为修正的Rankin-Scale(MRS)5-6。报告了特征重要性、辨别能力、校准和决策曲线分析。

结果:

  • 入选患者2261例,中位年龄75岁(64~83岁),女性46%,中位NIHSS9例(417例),单纯IVT 34%,单纯MT 41%,桥接25%。
  • 总体而言,有539人(24%)有FRT,仅MT患者(34%)比单独IVT患者(11%)更常见。特征重要性确定的临床变量(卒中严重程度、年龄、活动性癌症、卒中前残疾)、实验室值(血糖、CRP、肌酐)、成像生物标志物(脑白质高信号)和发病至入院时间最重要的预测因素。
  • 最终模型对3个月FRT的预测具有一定的区分性(AUC为0.87,95%CI为0.87-0.88),校正效果良好(Brier为0.12,0.11-0.12)。
  • 总体表现中等(F1-得分0.63±0.004),决策曲线分析表明,在较低的治疗门槛时,平均净收益较高(最高为0.8%)。

结论:该FRT预测模型有助于为共享决策提供信息,并确定在紧急情况下最相关的特征。虽然它在低资源的医疗保健环境中可能特别有用,但为了进一步提高预测性能,有必要纳入更多的多方面变量。

文献来源:Meinel T, Lerch C, Fischer U, et al. Multivariable Prediction Model for Futile Recanalization Therapies in Patients With Acute Ischemic Stroke [published online ahead of print, 2022 Jul 8]. Neurology. 2022;10.1212/WNL.0000000000200815. doi:10.1212/WNL.0000000000200815

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1806543, encodeId=1b3a18065438a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Nov 24 20:48:43 CST 2022, time=2022-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893548, encodeId=0735189354844, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri May 12 13:48:43 CST 2023, time=2023-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720481, encodeId=eaed1e20481a9, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Jun 14 02:48:43 CST 2023, time=2023-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262844, encodeId=95751262844ae, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 01 07:48:43 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010460, encodeId=6ff52010460b9, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Jul 25 18:48:43 CST 2023, time=2023-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242241, encodeId=6a7b124224132, content=很有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJzj1YsKnHUzS71cUQ4unTpIbhCh1o4OsSHf1m9LYsMbhib9F1avde0mmhC0JvZEsf1HIJobX8szuw/132, createdBy=ccae5142731, createdName=tz8029, createdTime=Wed Aug 31 11:33:51 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001925, encodeId=dfcc20019253c, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Sep 21 13:48:43 CST 2022, time=2022-09-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1806543, encodeId=1b3a18065438a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Nov 24 20:48:43 CST 2022, time=2022-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893548, encodeId=0735189354844, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri May 12 13:48:43 CST 2023, time=2023-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720481, encodeId=eaed1e20481a9, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Jun 14 02:48:43 CST 2023, time=2023-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262844, encodeId=95751262844ae, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 01 07:48:43 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010460, encodeId=6ff52010460b9, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Jul 25 18:48:43 CST 2023, time=2023-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242241, encodeId=6a7b124224132, content=很有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJzj1YsKnHUzS71cUQ4unTpIbhCh1o4OsSHf1m9LYsMbhib9F1avde0mmhC0JvZEsf1HIJobX8szuw/132, createdBy=ccae5142731, createdName=tz8029, createdTime=Wed Aug 31 11:33:51 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001925, encodeId=dfcc20019253c, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Sep 21 13:48:43 CST 2022, time=2022-09-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1806543, encodeId=1b3a18065438a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Nov 24 20:48:43 CST 2022, time=2022-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893548, encodeId=0735189354844, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri May 12 13:48:43 CST 2023, time=2023-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720481, encodeId=eaed1e20481a9, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Jun 14 02:48:43 CST 2023, time=2023-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262844, encodeId=95751262844ae, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 01 07:48:43 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010460, encodeId=6ff52010460b9, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Jul 25 18:48:43 CST 2023, time=2023-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242241, encodeId=6a7b124224132, content=很有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJzj1YsKnHUzS71cUQ4unTpIbhCh1o4OsSHf1m9LYsMbhib9F1avde0mmhC0JvZEsf1HIJobX8szuw/132, createdBy=ccae5142731, createdName=tz8029, createdTime=Wed Aug 31 11:33:51 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001925, encodeId=dfcc20019253c, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Sep 21 13:48:43 CST 2022, time=2022-09-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1806543, encodeId=1b3a18065438a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Nov 24 20:48:43 CST 2022, time=2022-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893548, encodeId=0735189354844, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri May 12 13:48:43 CST 2023, time=2023-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720481, encodeId=eaed1e20481a9, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Jun 14 02:48:43 CST 2023, time=2023-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262844, encodeId=95751262844ae, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 01 07:48:43 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010460, encodeId=6ff52010460b9, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Jul 25 18:48:43 CST 2023, time=2023-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242241, encodeId=6a7b124224132, content=很有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJzj1YsKnHUzS71cUQ4unTpIbhCh1o4OsSHf1m9LYsMbhib9F1avde0mmhC0JvZEsf1HIJobX8szuw/132, createdBy=ccae5142731, createdName=tz8029, createdTime=Wed Aug 31 11:33:51 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001925, encodeId=dfcc20019253c, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Sep 21 13:48:43 CST 2022, time=2022-09-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1806543, encodeId=1b3a18065438a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Nov 24 20:48:43 CST 2022, time=2022-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893548, encodeId=0735189354844, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri May 12 13:48:43 CST 2023, time=2023-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720481, encodeId=eaed1e20481a9, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Jun 14 02:48:43 CST 2023, time=2023-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262844, encodeId=95751262844ae, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 01 07:48:43 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010460, encodeId=6ff52010460b9, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Jul 25 18:48:43 CST 2023, time=2023-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242241, encodeId=6a7b124224132, content=很有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJzj1YsKnHUzS71cUQ4unTpIbhCh1o4OsSHf1m9LYsMbhib9F1avde0mmhC0JvZEsf1HIJobX8szuw/132, createdBy=ccae5142731, createdName=tz8029, createdTime=Wed Aug 31 11:33:51 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001925, encodeId=dfcc20019253c, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Sep 21 13:48:43 CST 2022, time=2022-09-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1806543, encodeId=1b3a18065438a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Nov 24 20:48:43 CST 2022, time=2022-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893548, encodeId=0735189354844, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri May 12 13:48:43 CST 2023, time=2023-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720481, encodeId=eaed1e20481a9, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Jun 14 02:48:43 CST 2023, time=2023-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262844, encodeId=95751262844ae, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 01 07:48:43 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010460, encodeId=6ff52010460b9, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Jul 25 18:48:43 CST 2023, time=2023-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242241, encodeId=6a7b124224132, content=很有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJzj1YsKnHUzS71cUQ4unTpIbhCh1o4OsSHf1m9LYsMbhib9F1avde0mmhC0JvZEsf1HIJobX8szuw/132, createdBy=ccae5142731, createdName=tz8029, createdTime=Wed Aug 31 11:33:51 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001925, encodeId=dfcc20019253c, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Sep 21 13:48:43 CST 2022, time=2022-09-21, status=1, ipAttribution=)]
    2022-08-31 tz8029

    很有收获

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1806543, encodeId=1b3a18065438a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Nov 24 20:48:43 CST 2022, time=2022-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893548, encodeId=0735189354844, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri May 12 13:48:43 CST 2023, time=2023-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720481, encodeId=eaed1e20481a9, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Jun 14 02:48:43 CST 2023, time=2023-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262844, encodeId=95751262844ae, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 01 07:48:43 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010460, encodeId=6ff52010460b9, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Jul 25 18:48:43 CST 2023, time=2023-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242241, encodeId=6a7b124224132, content=很有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJzj1YsKnHUzS71cUQ4unTpIbhCh1o4OsSHf1m9LYsMbhib9F1avde0mmhC0JvZEsf1HIJobX8szuw/132, createdBy=ccae5142731, createdName=tz8029, createdTime=Wed Aug 31 11:33:51 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001925, encodeId=dfcc20019253c, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Sep 21 13:48:43 CST 2022, time=2022-09-21, status=1, ipAttribution=)]
    2022-09-21 yinhl1978

相关资讯

空腹血糖升高,脑卒中风险高!全球疾病负担报告

终其一生,男性比女性高空腹血糖相关脑卒中发生风险更高。

卒中患者「早期康复」治疗为何如此重要?一组数据说清楚!

《2018-2021年度康复临床成果报告》发布,卒中康复亟需尽早启动治疗,不可忽视言语功能障碍和心理健康。

Stroke|天坛王伊龙:生活中简单的7件事与脑小血管疾病的关系

理想的LS7评分表明心血管健康状况良好,与CSVD总负担较低有关。

Cardiovasc Diabetol:TyG指数变化轨迹与高血压患者卒中风险的相关性

定期监测 TyG 指数可能有助于及时识别高血压患者中卒中风险较高的个体

Stroke:流感类疾病和疫苗接种对年轻人中风的影响如何?

ILI与年轻人和中年人的卒中风险增加有关,而任何类型的疫苗接种与年轻人的风险降低有关。

Stroke:缺血性中风和精神病史患者在再灌注治疗和时间延迟方面的差异性

几乎四分之一的缺血性卒中患者有精神疾病史。无论精神疾病的严重程度如何,这些患者接受再灌注治疗的可能性较小。

拓展阅读

J Hepatol:肝衰竭患者肝移植预后评分新模型

当肝硬化患者出现肝脏相关的并发症,如静脉曲张出血、腹水、肝性脑病或细菌感染时,称为失代偿性肝硬化,与预期寿命的减少有关,当其出现两个或更多器官衰竭时,28天病死率非常高,肝移植是目前唯一有效救治手段。

Journal of Hematology & Oncology:临床病理学特征的综合分析定义了免疫化学治疗地幔细胞淋巴瘤的新预后模型

在过去的二十年里,MCL患者的预后有明显改善,随着临床管理的发展,预计会进一步改善。本研究开发的创新预后模型将作为指导为MCL患者选择更合适的治疗策略的宝贵工具。

Journal of Hematology & Oncology:CAR-HEMATOTOX评分作为接受BCMA指导的CAR-T复发/难治性多发性骨髓瘤患者的毒性和反应的预后模型

本文突出了CAR-HEMATOTOX评分对接受BCMA指导的CAR-T的多发性骨髓瘤患者的毒性和治疗反应的预后效用。

TRANSPLANTATION:慢性肝病儿童的器官移植的及时和正确的分配模型

建立一个客观的预测模型能确保器官的正确和及时分配,同时提高 PELD/MELD 的敏感性,以进一步确保器官分配的准确性,降低儿科围移植期死亡率。

JNNP:结合生物标志物建立帕金森病预后模型

帕金森病(PD)是一种进行性神经退行性疾病。改善疾病以减缓进展速度仍然是帕金森病的一个关键目标。其进展速度具有实质性的临床异质性。这种可变性的基本基础尚不清楚,但可能与细胞易感性、炎症、致病蛋白的细胞

Ear Nose Throat J:慢性中耳炎患者听力恢复预后模型的开发和验证

调查了影响慢性中耳炎(COM)患者术后听力恢复的因素,建立了听力恢复的临床预测模型,并验证了该模型的准确性。

脑卒中一级预防的最佳证据总结

暂未更新 · 2024-01-10

成人脑卒中患者久坐行为管理的最佳证据总结

南昌大学护理学院 · 2024-01-10

脑卒中后认知功能障碍危险因素管理的证据总结

广西中医药大学护理学院 · 2023-10-01